GNAS抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using GNAS mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of MCF-7 cells using GNAS mouse mAb (green) and negative control (red).    

  
  

The GNAS antibody targets proteins encoded by the GNAS complex locus, a gene critical in G protein-coupled receptor (GPCR) signaling. GNAS produces multiple transcripts through alternative splicing and imprinting, with the most studied being the stimulatory G-protein α-subunit (Gsα). Gsα activates adenylate cyclase, generating cAMP, a key second messenger regulating cellular processes like proliferation and hormone response.

GNAS mutations or dysregulation are linked to diseases. Activating mutations (e.g., R201H) cause McCune-Albright syndrome (fibrous dysplasia, endocrine disorders) and sporadic endocrine tumors. In contrast, maternally inherited inactivating mutations lead to pseudohypoparathyroidism type 1A (PHP1A), characterized by hormone resistance, while paternal mutations result in pseudopseudohypoparathyroidism (PPHP) without endocrine abnormalities.

Antibodies against GNAS are vital tools in research and diagnostics. They help detect Gsα expression or post-translational modifications in tissues, aiding studies on GPCR signaling defects. In clinical settings, they assist in diagnosing GNAS-related disorders or identifying somatic mutations in tumors. However, challenges remain due to the locus’s complexity, including multiple isoforms and imprinting-specific expression, requiring careful validation of antibody specificity. Overall, GNAS antibodies contribute to understanding disease mechanisms and developing targeted therapies.